Zubsolv market share (rolling 4 weeks average) in August was unchanged compared to last month. Market share in volume reached 5.32% (5.34%) at the end of August, and TRx reached a market share of 5.19% (5.18%). The overall market for buprenorphine/naloxone based opioid addiction treatments continues to show a double digit growth rate. In August (rolling 4 weeks average) the y/y TRx growth rate was 10.6% (12.5%) and 10.5% (11.8%) in volume.